<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive cervical adenocarcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive cervical adenocarcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Invasive cervical adenocarcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marcela G del Carmen, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John O Schorge, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H553367437"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cervical cancer encompasses several histologic types, of which squamous cell carcinoma (SCC) is the most common (70 percent)  (<a class="graphic graphic_table graphicRef141016" href="/z/d/graphic/141016.html" rel="external">table 1</a>). The incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades; this cell type now accounts for approximately 25 percent of all invasive cervical cancers diagnosed in the United States [<a href="#rid1">1,2</a>]. Neuroendocrine (predominantly small cell poorly differentiated) carcinomas and other rare cell types together comprise 3 to 5 percent of all cases. (See  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a>.)</p><p>Most of our knowledge on the treatment of cervical cancer comes from studies in which the majority of the patients had SCC; adenocarcinoma has comprised, on average, 10 percent of the cases. Very few of these studies report separate outcomes for adenocarcinoma, and no prospective study has focused on the treatment of adenocarcinoma as the sole histology. As a result, our understanding of the natural history and optimal management of adenocarcinoma of the cervix is limited. However, as there are many similarities between adenocarcinoma and SCC of the cervix, they are treated the same at most institutions.</p><p>This topic will focus on unique issues pertaining to invasive cervical adenocarcinoma. Clinical features, staging, and management issues that are common to SCC and adenocarcinoma, as well as adenocarcinoma in situ, are discussed in depth separately. (See  <a class="medical medical_review" href="/z/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a> and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3218.html" rel="external">"Cervical adenocarcinoma in situ"</a>.)</p><p class="headingAnchor" id="H175461"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>There are both similarities and differences in the epidemiology of adenocarcinoma of the cervix compared with squamous cell carcinoma (SCC):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen</strong> – The incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades, particularly in younger patients [<a href="#rid3">3,4</a>]. One possible causative factor that has been proposed to explain this trend is an increased exposure to estrogen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pooled analysis of data from eight case-control studies suggests that endogenous estrogen (eg, obesity) has a stronger association with adenocarcinoma as compared with SCC [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exposure to exogenous estrogens (eg, hormonal contraception, postmenopausal estrogen therapy) is a risk factor for adenocarcinoma [<a href="#rid6">6-9</a>]. However, a systematic review concluded that use of oral contraceptives was a risk factor for both adenocarcinoma and SCC [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus (HPV)</strong> – Cervical adenocarcinoma shares some of the same risk factors with SCC, the most important of which is prolonged infection with high-risk subtypes of HPV, particularly subtypes 16 and 18 [<a href="#rid5">5,11,12</a>]. However, adenocarcinoma and SCC have slightly different associations with HPV genotypes [<a href="#rid12">12,13</a>]. The available data suggest that HPV 18 accounts for approximately 50 percent of adenocarcinomas compared with 15 percent of SCCs and that the proportion of adenocarcinomas associated with HPV 16 and 18 infections is higher in adenocarcinomas relative to that of SCC, which is associated with a greater diversity of HPV types [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – In contrast to its squamous counterpart, cigarette smoking does <strong>not</strong> appear to be a risk factor for adenocarcinoma [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parity</strong> – The pooled analysis of case-control studies above also suggested that parity has a <strong>weaker</strong> association with adenocarcinoma as compared with SCC [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H553367444"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) and International Endocervical Adenocarcinoma Criteria and Classification (IECC) system distinguishes cervical adenocarcinomas into those that are HPV associated or HPV independent  (<a class="graphic graphic_table graphicRef141016" href="/z/d/graphic/141016.html" rel="external">table 1</a>) [<a href="#rid15">15,16</a>]. </p><p>HPV-associated adenocarcinomas include:</p><p class="bulletIndent1"><span class="glyph">●</span>Usual type – Cervical adenocarcinomas of the usual endocervical type account for at least 80 percent of cervical adenocarcinomas. They are characterized by an irregular haphazard arrangement of glands lined by cells resembling those that line normal endocervical glands. </p><p></p><p class="bulletIndent1">Morphologic variations have been described and include:  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Villoglandular</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mucinous type – Mucinous types include intestinal, signet ring, or not otherwise specified</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Invasive stratified mucin producing intraepithelial lesion</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenosquamous</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mucoepidermoid</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenoid basal cell</p><p></p><p>HPV-independent adenocarcinomas include:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastric type</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clear cell type</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mesonephric type</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometrioid type – Endometrioid-type adenocarcinomas with the characteristic histology of tubular glands are infrequently diagnosed, but they have a better prognosis than adenocarcinomas of the usual endocervical type [<a href="#rid17">17</a>]. These tumors display histologic features that are identical to endometrial carcinomas, and the possibility of a primary endometrial adenocarcinoma with endocervical extension or drop metastasis must be excluded before the diagnosis of a primary endocervical endometrioid adenocarcinoma is established. Despite the better prognosis, management for endometrioid histology is generally the same as for other cervical adenocarcinomas. (See <a class="local">'Specific management issues'</a> below.)</p><p></p><p>The precursor lesion of most invasive cervical adenocarcinomas is believed to be adenocarcinoma in situ (AIS) (see  <a class="medical medical_review" href="/z/d/html/3218.html" rel="external">"Cervical adenocarcinoma in situ"</a>). By contrast, adenosquamous carcinoma is a tumor composed of admixed malignant glandular and squamous elements. It does not appear to originate from AIS and demonstrates more aggressive features than other cervical adenocarcinomas, such as higher tumor grade and lymphovascular invasion [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H175741"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations of cervical adenocarcinoma are the same as for squamous cell carcinoma. Many patients are asymptomatic, and, where cervical cancer screening is routinely performed, cervical adenocarcinoma is most commonly detected through cervical cytology, especially when the endocervical canal is adequately sampled. When symptoms occur, patients are most likely to present with postcoital bleeding. In some patients, a cervical mass is discovered upon pelvic examination that is performed for other indications. (See  <a class="medical medical_review" href="/z/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p class="headingAnchor" id="H175763"><span class="h1">DIAGNOSIS AND STAGING</span><span class="headingEndMark"> — </span>As with squamous cell carcinoma (SCC), cervical adenocarcinoma is diagnosed with a cervical biopsy. The depth of invasion, which correlates with the incidence of metastatic disease, is measured from the luminal surface of the tumor or overlying benign epithelium to the deepest invasive tumor nest [<a href="#rid19">19</a>].</p><p>The vast majority of adenocarcinomas have an obvious invasive component. The exception to this is microinvasive disease. Microinvasive cervical adenocarcinoma (also termed early invasive adenocarcinoma, International Federation of Gynecology and Obstetrics [FIGO]/American Joint Committee on Cancer [AJCC] stage IA1 or 1A2 disease  (<a class="graphic graphic_table graphicRef139268" href="/z/d/graphic/139268.html" rel="external">table 2</a>)) is most commonly detected postoperatively on a conization performed for presumed adenocarcinoma in situ (AIS). (See <a class="local">'Staging system'</a> below.)</p><p>A diagnostic excisional procedure (eg, cold knife conization, loop electrosurgical excision procedure) with a negative margin is required to define the microinvasive lesion, and an endocervical curettage (ECC) is recommended to confirm the absence of additional disease. This is particularly important for cervical adenocarcinoma since, in contrast to cervical SCC, noncontiguous lesions ("skip lesions") are often found. In general, we do not recommend additional biopsies in the setting of a negative conization margin and negative ECC.</p><p>If the excisional margin or ECC is positive for invasive tumor, a second conization is mandatory. If there is no residual disease on the second procedure, then a diagnosis of microinvasive (stage IA1 or IA2) disease can safely be made. If the second conization demonstrates additional invasive disease, then it should be classified as invasive disease and staged accordingly.</p><p class="headingAnchor" id="H453094955"><span class="h2">Staging system</span><span class="headingEndMark"> — </span>The staging schema for cervical adenocarcinoma and its variants is the same as for SCC. The FIGO staging system and the AJCC tumor, node, and metastasis (TNM) staging system are presented in the tables  (<a class="graphic graphic_table graphicRef119447" href="/z/d/graphic/119447.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef139268" href="/z/d/graphic/139268.html" rel="external">table 2</a>) [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="headingAnchor" id="H453094962"><span class="h2">Staging workup</span><span class="headingEndMark"> — </span>As with SCC, the 2018 FIGO guidelines allow the provider to use imaging (ie, ultrasound, computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography) to provide information on tumor size, nodal status, and local or systemic spread. However, it is recognized that there will be limitations in imaging (eg, in lower middle-income countries, access to these extensive imaging services is often sparse or not available).</p><p>Additionally, image-guided fine needle aspiration or biopsy or surgical excision of suspicious sites is allowed to supplement clinical findings and provide a more accurate assignment of disease stage.</p><p>FIGO no longer mandates any investigative procedures; however, in patients with frank invasive carcinoma, a conventional chest radiograph and assessment of hydronephrosis (with renal ultrasound, intravenous pyelography, CT, or MRI) should be performed. The bladder and rectum are evaluated by cystoscopy and sigmoidoscopy if the patient is clinically symptomatic. Cystoscopy is also recommended in cases of a barrel-shaped endocervical growth and in cases where the growth has extended to the anterior vaginal wall. Suspected bladder or rectal involvement should be confirmed by biopsy. (See <a class="local">'Role and extent of lymphadenectomy'</a> below and <a class="local">'Locoregionally advanced (IIB to IVA) disease'</a> below and  <a class="medical medical_review" href="/z/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes", section on 'Staging procedure'</a>.)</p><p class="headingAnchor" id="H1362292"><span class="h1">PROGNOSTIC FACTORS AND DIFFERENCES IN OUTCOME COMPARED WITH SCC</span><span class="headingEndMark"> — </span>The major prognostic factors for cervical adenocarcinoma are the same as for squamous cell carcinoma (SCC), including stage, nodal status, tumor volume, depth of cervical stromal invasion, lymphovascular space invasion, grade, and human papillomavirus (HPV) status [<a href="#rid15">15,22-24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Prognosis'</a>.)</p><p>Some potential differences in prognostic factors and outcomes between adenocarcinoma and SCC are discussed here.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic type</strong> – As with SCC, HPV status appears to affect prognosis, with HPV-related compared with HPV-independent cancers conferring a better prognosis [<a href="#rid15">15,25</a>]. However, there is controversy as to whether histologic type itself is an independent prognostic factor in cervical cancer [<a href="#rid26">26-38</a>]. While older studies suggest that adenocarcinoma compared with SCC is associated with worse outcomes, a 2020 study showed that, when adjusted for stage, prognosis is similar [<a href="#rid38">38</a>]. In this retrospective study of 4131 patients with either adenocarcinoma or SCC of the cervix from the Surveillance, Epidemiology, and End Results (SEER) database, five-year overall survival was similar between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patterns of dissemination </strong>– Ovarian metastases are more common with adenocarcinoma than with SCC (5.0 versus 0.8 percent in one series [<a href="#rid39">39</a>]). As a result, we usually recommend bilateral oophorectomy at the time of hysterectomy for those with adenocarcinoma (but not SCC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment response</strong> – While treatment for adenocarcinoma generally follows the same principles established for SCC, patients with adenocarcinoma may respond differently to specific components of therapy. For patients with adenocarcinoma compared with SCC:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjuvant external beam radiation therapy (EBRT) may be more effective – In one randomized trial of 277 patients (59 with non-SCC histology) with surgically treated stage IB cervical cancer, negative nodes, and at least two adverse prognostic factors, the addition of EBRT compared with observation reduced the risk of recurrence for non-SCC tumors more than for SCC tumors (recurrence rate with EBRT versus observation was 9 versus 44 percent; the corresponding values for SCC were 20 versus 28 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>RT alone may be <strong>less</strong> effective – In another randomized trial of 243 patients (50 adenocarcinomas) with resected stage IA2, IB, or IIA cervical cancer with high-risk features treated with chemoradiotherapy versus RT alone, patients with adenocarcinoma had a worse prognosis than SCC when treated with RT alone; this difference disappeared in patients who received chemotherapy in addition to RT [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Surgery, compared with RT alone, may be more effective for patients with adenocarcinoma. In another randomized trial including 343 patients (46 adenocarcinomas) with stage IB or IIA cervical cancer who were assigned to surgery or radical RT, five-year disease-free and overall survival were not different between the surgery and RT arms; however, among those with adenocarcinoma, there appeared to be a significant advantage for surgery compared with RT alone (five-year overall survival 70 versus 59 percent, disease-free survival 66 versus 47 percent) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">However, these results are from unplanned subset analyses of small groups of patients, and they should be considered hypothesis-generating at best.</p><p></p><p class="headingAnchor" id="H553367451"><span class="h1">SPECIFIC MANAGEMENT ISSUES</span><span class="headingEndMark"> — </span>General principles of management, particularly where they vary from those for squamous cell carcinoma (SCC), are presented here.</p><p class="headingAnchor" id="H553368259"><span class="h2">Microinvasive (IA1 and IA2) disease</span><span class="headingEndMark"> — </span>Management of microinvasive cervical adenocarcinoma depends upon patient age and desire to maintain fertility. The prognosis of microinvasive adenocarcinoma is generally excellent, and conservative, nonradical surgery is appropriate for some patients [<a href="#rid43">43,44</a>]. As an example, an overall relapse rate of 3 percent was found in a national United States cancer database (Surveillance, Epidemiology, and End Results [SEER]) study of 1170 patients with surgically treated microinvasive cervical adenocarcinoma [<a href="#rid45">45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IA1</strong> – For patients wishing to preserve fertility, cold knife conization with widely negative margins is acceptable. For patients who have completed childbearing or for postmenopausal patients, simple hysterectomy is a reasonable option since surveillance of the endocervical canal is challenging over time. Pelvic lymphadenectomy is not necessary. (See <a class="local">'Fertility preservation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IA2</strong> – We tend to perform a modified radical hysterectomy for stage IA2 lesions; the added surgical morbidity of this approach compared with simple hysterectomy is minimal when performed by experienced gynecologic oncologists. In a modified radical hysterectomy, the uterine artery is ligated where it crosses over the ureter; the uterosacral and cardinal ligaments are divided midway toward their attachment to the sacrum and the pelvic side wall, respectively, so that the parametrium medial to the ureter is removed; and the upper one-third of the vagina is resected. The Piver-Rutledge-Smith classification of hysterectomy is shown in the table  (<a class="graphic graphic_table graphicRef57850" href="/z/d/graphic/57850.html" rel="external">table 4</a>); other classification systems have been published (eg, Querleu and Morrow  (<a class="graphic graphic_table graphicRef140316" href="/z/d/graphic/140316.html" rel="external">table 5</a>)) [<a href="#rid46">46,47</a>]. We also include sentinel lymph node biopsy or a pelvic lymph node dissection for stage IA2 disease. (See <a class="local">'Role and extent of lymphadenectomy'</a> below and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3303.html" rel="external">"Radical hysterectomy", section on 'Types of radical hysterectomy'</a>.)</p><p></p><p class="headingAnchor" id="H553367459"><span class="h2">Invasive early stage (IB and IIA) disease</span><span class="headingEndMark"> — </span>Stage IB and IIA cervical cancer can be cured by either surgery (usually radical hysterectomy, bilateral salpingo-oophorectomy, and sentinel node biopsy or pelvic lymph node dissection) or radiation therapy (RT), which is typically administered with concurrent chemotherapy (ie, chemoradiotherapy). (See  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Surgery preferred over radiation'</a>.)</p><p>In general, the management of early-stage invasive cervical adenocarcinoma and its variants is similar, stage for stage, to that of SCC, with some minor modifications [<a href="#rid19">19,48</a>]. As an example, due to the higher risk of ovarian metastases, patients with nonmicroscopic cervical adenocarcinoma who are appropriate for surgical treatment should be counseled about oophorectomy at the time of hysterectomy. (See <a class="local">'Prognostic factors and differences in outcome compared with SCC'</a> above.)</p><p>The general principles that guide therapy are to offer patients single-modality treatment if at all possible and to avoid radical surgery followed by chemoradiotherapy. Surgery is generally preferred over initial chemoradiotherapy if the patient is an appropriate candidate for surgery, given the lower rate of long-term treatment-related adverse effects [<a href="#rid48">48,49</a>]. However, if risk factors are identified pretreatment (eg, evidence of lymph node involvement on pretreatment imaging, tumor size &gt;4 cm, deep stromal invasion to the middle or deep one-third, or lymphovascular space invasion as seen in the initial biopsy) that indicate the need for adjuvant therapy after surgery, then we prefer upfront chemoradiotherapy. (See  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'High-risk disease'</a>.)</p><p>The preference for surgery is based on data from a prospective trial in which 343 patients with stage IB and IIA cervical carcinoma (14 percent adenocarcinoma) were randomly assigned to primary surgery or RT (but without concurrent chemotherapy) [<a href="#rid42">42,50</a>]. At a median follow-up of 87 months, the five-year overall and disease-free survival rates were the same for both treatment groups (83 and 74 percent, respectively). However, multivariate analysis demonstrated a survival advantage for patients with adenocarcinoma who underwent primary surgery. It remains to be determined whether this result was due to an increased effectiveness of surgery or the absence of a benefit from RT (possibly due to the lack of concurrent chemotherapy) in patients with adenocarcinoma.</p><p>As noted above, some data raise the possibility that adenocarcinomas have a poorer outcome with RT alone than do SCCs, but that relative radioresistance might be overcome through the use of concurrent chemotherapy. As a result, when RT is administered for adenocarcinoma, we usually give concurrent cisplatin-based chemotherapy. (See <a class="local">'Prognostic factors and differences in outcome compared with SCC'</a> above and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a>.)</p><p class="headingAnchor" id="H10754335"><span class="h3">Posttreatment extrafascial hysterectomy</span><span class="headingEndMark"> — </span>Extrafascial hysterectomy is not routinely performed following chemoradiotherapy because chemoradiotherapy alone yields low local recurrence rates. The benefit of postradiotherapy surgery was addressed in a GOG trial in which 256 patients with cervical cancer &gt;4 cm were randomly assigned to RT alone or RT followed by surgery [<a href="#rid51">51</a>]. While the surgery group had lower rates of local relapse at five years (14 versus 27 percent), survival was not improved.</p><p>A simple extrafascial hysterectomy could be considered for patients at high risk for a poor outcome with chemoradiotherapy alone, although there is no consensus as to which patients fit this category. We consider this approach for patients with early-stage cervical cancer and no evidence of nodal involvement who have an initially large cervical lesion (&gt;7 cm), lower uterine segment involvement, or a high residual tumor volume after chemoradiotherapy [<a href="#rid52">52</a>]. Although such an approach has the potential to enhance local control, patients will be exposed to the combined morbidity of radical surgery and RT. (See  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Role of hysterectomy after chemoradiation'</a>.)</p><p class="headingAnchor" id="H381109989"><span class="h3">Role and extent of lymphadenectomy</span><span class="headingEndMark"> — </span>Nodal metastases are the most important prognostic variable for cervical cancer. Lymph node metastases portend a poor outcome, particularly among those with adenocarcinoma [<a href="#rid29">29</a>]. Detecting their presence is crucial to guide treatment planning.</p><p>Pelvic lymph node assessment with either sentinel node mapping or lymphadenectomy is a mandatory component of initial surgery for early-stage, operable cervical adenocarcinoma (stage IA2, IB1, and IIA disease) as it is with SCC. However, unless there is gross evidence of nodal or adnexal disease at the time of visual inspection during surgery, extension of the node dissection to include the paraaortic lymph nodes is not mandatory [<a href="#rid53">53</a>]. We consider that patients who have suspicious lymph nodes on pretreatment imaging are more appropriate for initial chemoradiotherapy than surgery. The role of therapeutic debulking lymphadenectomy in such patients is controversial and discussed below. (See <a class="local">'Role of therapeutic lymphadenectomy'</a> below.)</p><p class="headingAnchor" id="H453095097"><span class="h3">Indications for adjuvant therapy after hysterectomy</span><span class="headingEndMark"> — </span>As with cervical SCC, patients with <strong>one or more</strong> of the following findings are considered to be at <strong>high risk</strong> for recurrent disease and should receive adjuvant chemoradiotherapy following hysterectomy:</p><p class="bulletIndent1"><span class="glyph">●</span>Positive or close resection margins</p><p class="bulletIndent1"><span class="glyph">●</span>Positive lymph nodes</p><p class="bulletIndent1"><span class="glyph">●</span>Microscopic parametrial involvement</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'High-risk disease'</a>.)</p><p>Adjuvant therapy is also recommended for patients at intermediate risk of recurrence (large tumor size, deep cervical stromal invasion to the middle or deep one-third, or lymphovascular space invasion), but at least for SCC, there is less consensus on the optimal form of adjuvant therapy (RT versus chemoradiotherapy). In view of the above data suggesting that adenocarcinomas have a poorer outcome with RT alone than do SCCs, but that relative radioresistance might be overcome through the use of concurrent chemotherapy, we administer concurrent cisplatin-based chemotherapy. (See <a class="local">'Prognostic factors and differences in outcome compared with SCC'</a> above and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Intermediate-risk disease'</a>.)</p><p class="headingAnchor" id="H553367466"><span class="h2">Locoregionally advanced (IIB to IVA) disease</span><span class="headingEndMark"> — </span>For patients with locoregionally advanced cervical SCC, primary RT has been the treatment of choice at most institutions, although practice varies. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest either radical hysterectomy or initial chemoradiotherapy in this setting [<a href="#rid54">54</a>].</p><p>However, in our view, these patients should be approached initially with chemoradiotherapy. One of the main arguments against a primary surgical approach in this setting is the high potential for multimodality therapy, given that the majority of patients will have high-risk or intermediate-risk disease for which postoperative chemoradiotherapy is recommended. (See  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Definition of locally advanced-stage cervical cancer'</a> and  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a>.)</p><p>Multiple randomized phase III trials, which enrolled predominantly SCC, as well as a meta-analysis have confirmed the survival benefit of adding cisplatin-based concurrent chemotherapy to RT for primary treatment of locally advanced cervical cancer. (See  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Primary chemoradiation'</a>.)</p><p>It is reasonable to apply these results to adenocarcinoma and its variants for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>These trials included patients with adenocarcinoma histology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is evidence that early-stage cervical adenocarcinomas are sensitive to cisplatin-based chemoradiation [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenocarcinoma-specific phase III trials cannot feasibly be conducted due to the low incidence of glandular disease.</p><p></p><p>However, the dismal prognosis of all histologic types of advanced disease, especially stage III and IV, emphasizes the need for novel approaches [<a href="#rid52">52,55</a>].</p><p class="headingAnchor" id="H453095633"><span class="h3">Role of therapeutic lymphadenectomy</span><span class="headingEndMark"> — </span>The role of therapeutic lymphadenectomy in patients undergoing primary chemoradiotherapy for locoregionally advanced cervical cancer is controversial. Surgical staging is the most accurate method of determining lymph node involvement, which is one of the most important prognostic factors. In addition, there is a potential therapeutic survival benefit of resecting lymph nodes, particularly bulky nodes, prior to chemoradiotherapy, but this has not been proven.</p><p>For both cervical SCC and adenocarcinoma, some clinicians use the results of radiographic staging studies to select patients for a therapeutic lymphadenectomy. Pre-irradiation staging lymphadenectomy (which can be accomplished laparoscopically or robotically) may be offered to medically fit patients if they have evidence of bulky nodes on computed tomography (CT) scan or if a pretreatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) or PET/CT shows FDG uptake in the region of the infrarenal paraaortic or pelvic lymph nodes. If both are negative, routine staging lymphadenectomy is not performed. Guidelines from the NCCN suggest consideration of an extraperitoneal lymph node in this situation [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Pretreatment evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Treatment of para-aortic nodes'</a>.)</p><p>Given the controversy as to whether debulking of nodes is associated with a real survival advantage, we generally do not perform a therapeutic lymphadenectomy in patients undergoing primary chemoradiotherapy who have bulky adenopathy identified on pretreatment imaging. However, this is a controversial area, and some clinicians would recommend removal of suspicious nodes in good surgical candidates.</p><p class="headingAnchor" id="H453095363"><span class="h3">Neoadjuvant chemotherapy</span><span class="headingEndMark"> — </span>SCC of the cervix is a chemosensitive neoplasm particularly when cisplatin-based regimens are used, and neoadjuvant chemotherapy is an accepted approach for patients with locally advanced disease. (See  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Neoadjuvant chemotherapy'</a>.)</p><p>Adenocarcinomas are similarly chemotherapy sensitive, at least in the setting of advanced disease [<a href="#rid26">26,56</a>]. The use of neoadjuvant chemotherapy may be beneficial in selected patients [<a href="#rid57">57,58</a>], but whether this strategy provides superior outcomes over chemoradiotherapy is unknown.</p><p>In our view, this approach should be considered experimental for adenocarcinomas and not pursued outside of the context of a clinical trial.</p><p class="headingAnchor" id="H553367473"><span class="h2">Stage IVB, persistent and recurrent disease</span></p><p class="headingAnchor" id="H453095659"><span class="h3">Surgery and/or RT for localized recurrence</span><span class="headingEndMark"> — </span>Following radical hysterectomy or definitive chemoradiotherapy for early-stage cervical SCC, the predominant site of disease recurrence is local (vaginal apex) or regional (pelvic sidewall). The same holds true for adenocarcinoma. Exenterative surgery is an option only for those few patients with centrally relapsed disease. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Candidates for surgical resection'</a>.)</p><p class="headingAnchor" id="H453095652"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Patients with more extensive primary or locoregionally relapsed disease or distant metastatic disease are usually treated with chemotherapy. Small prospective studies have evaluated the response of adenocarcinoma to chemotherapy [<a href="#rid26">26,56,59-61</a>], but in general, it is managed similarly to SCC. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Metastatic disease'</a>.)</p><p>In addition, the GOG no longer conducts clinical trials in non-SCC cervical carcinoma because it was deemed not to be feasible, and the available data suggest similar outcomes when nonsquamous and squamous cervical cancers are treated with platinum-based combination chemotherapy [<a href="#rid26">26</a>].</p><p>We prefer that eligible patients enroll in clinical trials testing new strategies. However, if a clinical trial is not available or feasible, we treat these patients similar to those with SCC. Our preferred chemotherapy regimen consists of a platinum-based combination (eg, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>). On the basis of the results of GOG 240, we also incorporate the angiogenesis inhibitor <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in the first-line treatment setting. This study showed a significant improvement in median overall survival (OS) associated with the incorporation of bevacizumab (17 months) when compared with use of chemotherapy alone (13.3 months, hazard ratio 0.71, 98% CI 0.54-0.95) [<a href="#rid62">62</a>]. The results of GOG 240 are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Initial treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Metastatic disease'</a>.)</p><p>For patients with a poor performance status and those who progress following first-line therapy, acceptable options include single-agent chemotherapy, best supportive care, and/or palliative RT. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Second-line therapy'</a>.)</p><p class="headingAnchor" id="H550393653"><span class="h3">Surgery for metastatic disease</span><span class="headingEndMark"> — </span>Surgical resection may be useful in carefully selected patients with cervical adenocarcinomas who have isolated pulmonary metastases. (See  <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"</a> and  <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology"</a>.)</p><p class="headingAnchor" id="H553367480"><span class="h2">Fertility preservation</span><span class="headingEndMark"> — </span>The management dilemma in patients with cervical adenocarcinoma who wish to preserve fertility is complicated by the inherent risks of residual disease and the relatively poor predictive value of conization margins. This is of somewhat greater concern than with squamous disease, since adenocarcinoma tends to be multifocal. Fertility preservation in patients with cervical cancer is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3200.html" rel="external">"Fertility-sparing surgery for cervical cancer"</a>.)</p><p class="headingAnchor" id="H553367487"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>The optimal surveillance strategy has not been established, and clinical practice is variable. Posttreatment surveillance for invasive cervical cancer is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3227.html" rel="external">"Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance"</a>.)</p><p class="headingAnchor" id="H376746935"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113940.html" rel="external">"Society guideline links: Treatment of cervical cancer"</a>.)</p><p class="headingAnchor" id="H18235885"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15414.html" rel="external">"Patient education: Cervical cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/859.html" rel="external">"Patient education: Cervical cancer treatment; early-stage cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H176666"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – Cervical adenocarcinoma comprises 25 percent of invasive cervical cancers; squamous cell carcinoma (SCC) account for 70 percent. Some risk factors for cervical adenocarcinoma are shared with squamous disease, particularly infection with high-risk subtypes of human papillomavirus (HPV). By contrast, cigarette smoking does not appear to be a risk factor for adenocarcinoma. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Many patients with cervical adenocarcinoma are asymptomatic. When symptoms occur, patients are most likely to present with postcoital bleeding. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and staging</strong> – Cervical adenocarcinoma is diagnosed with a cervical biopsy. Conization is required to define a microinvasive lesion, and a negative margin is required to confirm the diagnosis. (See <a class="local">'Diagnosis and staging'</a> above.)</p><p></p><p class="bulletIndent1">The staging system used for cervical adenocarcinoma is the same as for SCC  (<a class="graphic graphic_table graphicRef119447" href="/z/d/graphic/119447.html" rel="external">table 3</a>). We usually perform both a positron emission tomography/computed tomography and magnetic resonance imaging in nonmicroscopic invasive and more advanced cervical adenocarcinoma to help guide treatment. (See <a class="local">'Diagnosis and staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of microinvasive disease</strong> – Management of microinvasive (stage IA1 to IA2) cervical adenocarcinoma depends on patient age and desire to maintain fertility. The prognosis of microinvasive disease is excellent, and conservative, nonradical surgery is appropriate for some patients. (See <a class="local">'Microinvasive (IA1 and IA2) disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage IA1</strong> – For most patients with stage IA1 cervical adenocarcinoma, we suggest simple hysterectomy rather than radical hysterectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pelvic lymphadenectomy is not necessary. Conization is a reasonable option in patients who wish to preserve fertility and who do not have lymphovascular space invasion. (See <a class="local">'Microinvasive (IA1 and IA2) disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage IA2</strong> – For patients with stage IA2 cervical adenocarcinoma, we suggest modified radical hysterectomy rather than simple hysterectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We also perform pelvic lymphadenectomy in these patients. Radical trachelectomy is a reasonable option in patients who wish to preserve fertility and who do not have lymph node metastases and/or widespread evidence of lymphovascular space invasion. (See <a class="local">'Microinvasive (IA1 and IA2) disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of invasive disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Most patients with</strong> <strong>stage IB or IIA1</strong> – For most patients with stage IB or IIA1 cervical adenocarcinoma who are appropriate surgical candidates, we suggest initial surgery (radical hysterectomy, bilateral salpingo-oophorectomy, plus sentinel node biopsy or pelvic lymph node dissection) rather than primary chemoradiotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Invasive early stage (IB and IIA) disease'</a> above and <a class="local">'Role and extent of lymphadenectomy'</a> above.)</p><p></p><p class="bulletIndent2">The presence of positive or close resection margins, positive lymph nodes, or microscopic parametrial involvement indicates a high risk for recurrence. As with SCC, we recommend postoperative cisplatin-based concomitant chemoradiotherapy rather than adjuvant radiation therapy (RT) alone for these patients (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Although the optimal regimen has not been established, we suggest weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (40 mg/m<sup>2</sup> to a cumulative dose of at least 200 mg/m<sup>2</sup>) during RT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Indications for adjuvant therapy after hysterectomy'</a> above and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Surgery preferred over radiation'</a>.)</p><p></p><p class="bulletIndent2">As with SCC, we recommend adjuvant RT after hysterectomy for patients who are at intermediate risk of recurrence (large tumor size, deep cervical stromal invasion to the middle or deep one-third, or lymphovascular space invasion) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest adding concomitant chemotherapy to adjuvant RT for patients with intermediate-risk disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Indications for adjuvant therapy after hysterectomy'</a> above and  <a class="medical medical_review" href="/z/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Surgery preferred over radiation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selected candidates for initial chemoradiation</strong> – For certain subsets of patients with invasive cervical adenocarcinoma, we suggest initial chemoradiation rather than surgery (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). These include patients with the following (see  <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Primary chemoradiation'</a> and <a class="local">'Invasive early stage (IB and IIA) disease'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Locoregionally advanced stage IIB to IVA disease  (<a class="graphic graphic_table graphicRef119447" href="/z/d/graphic/119447.html" rel="external">table 3</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Bulky early-stage disease (ie, stage IB2, IIA2)</p><p class="bulletIndent3"><span class="glyph">-</span>Evidence of lymph node involvement by imaging or clinical examination</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with locoregionally advanced disease</strong> – For patients with locoregionally advanced disease, we suggest not pursuing neoadjuvant chemotherapy followed by hysterectomy outside of the context of a clinical trial (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Neoadjuvant chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with small tumors</strong> – In general, for patients with small tumors &lt;2 cm in size without lymphovascular space invasion, the survival difference between adenocarcinoma and SCC is negligible. Surgical management results in low recurrence rates and high overall survival rates with no differences in outcome related to histologic type. (See <a class="local">'Prognostic factors and differences in outcome compared with SCC'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other patients</strong> – Other patients (eg, lymphovascular space invasion, tumor size &gt;4 cm, deep stromal invasion to the middle or deep one-third) have worse prognosis and distant failure is more common when chemotherapy is omitted. (See <a class="local">'Invasive early stage (IB and IIA) disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated, recurrent, or persistent disease</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exenterative surgery is an option only for those few patients with centrally relapsed disease. (See <a class="local">'Surgery and/or RT for localized recurrence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a good performance status who wish to receive chemotherapy, and who are able to tolerate it, we suggest a platinum-based combination regimen plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in the first-line setting rather than chemotherapy alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients who are not candidates for bevacizumab should receive combination chemotherapy. (See <a class="local">'Chemotherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Initial treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Metastatic disease'</a>.)</p><p></p><p class="bulletIndent2">The choice of the specific regimen should be based upon prior toxicity, preexisting morbidity, scheduling considerations, and patient preference. A standard regimen is <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. (See <a class="local">'Chemotherapy'</a> above and  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Metastatic disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical resection is an alternative to chemotherapy for highly selected patients with isolated, potentially resectable pulmonary metastases. (See  <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Gynecologic cancers'</a> and  <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a poor performance status and those who progress following first-line therapy, acceptable options include single-agent chemotherapy, best supportive care, and/or palliative RT. (See  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Second-line therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Management of acutely symptomatic patients'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">SEER data for 2003-2007: http://seer.cancer.gov/ (Accessed on September 21, 2017).</li><li><a class="nounderline abstract_t">Alfsen GC, Thoresen SO, Kristensen GB, et al. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000; 89:1291.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59:38.</a></li><li><a class="nounderline abstract_t">Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.</a></li><li><a class="nounderline abstract_t">Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303.</a></li><li><a class="nounderline abstract_t">Quint KD, de Koning MN, van Doorn LJ, et al. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 2010; 117:297.</a></li><li><a class="nounderline abstract_t">Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001; 10:171.</a></li><li><a class="nounderline abstract_t">Lacey JV Jr, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003; 98:814.</a></li><li><a class="nounderline abstract_t">Lacey JV Jr, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000; 77:149.</a></li><li><a class="nounderline abstract_t">Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.</a></li><li><a class="nounderline abstract_t">Dahlström LA, Ylitalo N, Sundström K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010; 127:1923.</a></li><li><a class="nounderline abstract_t">Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121:32.</a></li><li><a class="nounderline abstract_t">Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005; 103:1258.</a></li><li><a class="nounderline abstract_t">International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118:1481.</a></li><li><a class="nounderline abstract_t">Höhn AK, Brambs CE, Hiller GGR, et al. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd 2021; 81:1145.</a></li><li><a class="nounderline abstract_t">Stolnicu S. Cervical cancer: what's new in classification, morphology, molecular findings and prognosis of glandular precursor and invasive lesions. Diagn Histopathol 2021; 27:483.</a></li><li class="breakAll">Wright TC, Ferenczy A, Kurman RJ. Carcinoma and other tumors of the cervix. In: Blaustein’s Pathology of the Female Genital Tract., 4th edition, Robert J. Kurman (Ed), Springer-Verlag, New York 1994.</li><li><a class="nounderline abstract_t">Wang SS, Sherman ME, Silverberg SG, et al. Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study. Gynecol Oncol 2006; 103:541.</a></li><li><a class="nounderline abstract_t">Schorge JO, Lee KR, Flynn CE, et al. Stage IA1 cervical adenocarcinoma: definition and treatment. Obstet Gynecol 1999; 93:219.</a></li><li><a class="nounderline abstract_t">Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin 2021; 71:287.</a></li><li class="breakAll">The New (Version 9) American Joint Committee on Cancer Tumor, Node, Metastasis Staging for Cervical Cancer. ACS Journals. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21663 (Accessed on October 08, 2021).</li><li><a class="nounderline abstract_t">Kilgore LC, Soong SJ, Gore H, et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol 1988; 31:137.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Morris M, Oswald MJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990; 65:2507.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Burke TW, Delclos L, et al. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol 1991; 41:199.</a></li><li><a class="nounderline abstract_t">Stolnicu S, Hoang L, Chiu D, et al. Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol 2019; 43:466.</a></li><li><a class="nounderline abstract_t">Kastritis E, Bamias A, Efstathiou E, et al. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol 2005; 99:376.</a></li><li><a class="nounderline abstract_t">Lee KB, Lee JM, Park CY, et al. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer 2006; 16:1569.</a></li><li><a class="nounderline abstract_t">Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 2012; 125:292.</a></li><li><a class="nounderline abstract_t">Macdonald OK, Chen J, Dodson M, et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009; 32:411.</a></li><li><a class="nounderline abstract_t">Davy ML, Dodd TJ, Luke CG, Roder DM. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101:38.</a></li><li><a class="nounderline abstract_t">Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 79:289.</a></li><li><a class="nounderline abstract_t">Lee YY, Choi CH, Kim TJ, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 2011; 120:439.</a></li><li><a class="nounderline abstract_t">Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012; 125:287.</a></li><li><a class="nounderline abstract_t">Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88:1361.</a></li><li><a class="nounderline abstract_t">Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003; 9:4145.</a></li><li><a class="nounderline abstract_t">Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000; 26:464.</a></li><li><a class="nounderline abstract_t">Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 1995; 76:1948.</a></li><li><a class="nounderline abstract_t">Tian T, Gong X, Gao X, et al. Comparison of survival outcomes of locally advanced cervical cancer by histopathological types in the surveillance, epidemiology, and end results (SEER) database: a propensity score matching study. Infect Agent Cancer 2020; 15:33.</a></li><li><a class="nounderline abstract_t">Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006; 101:234.</a></li><li><a class="nounderline abstract_t">Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.</a></li><li><a class="nounderline abstract_t">Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.</a></li><li><a class="nounderline abstract_t">Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.</a></li><li><a class="nounderline abstract_t">Reynolds EA, Tierney K, Keeney GL, et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol 2010; 116:1150.</a></li><li><a class="nounderline abstract_t">Hou J, Goldberg GL, Qualls CR, et al. Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol 2011; 121:135.</a></li><li><a class="nounderline abstract_t">Smith HO, Qualls CR, Romero AA, et al. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecol Oncol 2002; 85:229.</a></li><li><a class="nounderline abstract_t">Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol 2008; 9:297.</a></li><li><a class="nounderline abstract_t">Querleu D, Cibula D, Abu-Rustum NR. 2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy. Ann Surg Oncol 2017; 24:3406.</a></li><li><a class="nounderline abstract_t">Schorge JO, Lee KR, Lee SJ, et al. Early cervical adenocarcinoma: selection criteria for radical surgery. Obstet Gynecol 1999; 94:386.</a></li><li><a class="nounderline abstract_t">Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2010; :CD006248.</a></li><li><a class="nounderline abstract_t">Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2013; :CD006248.</a></li><li><a class="nounderline abstract_t">Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003; 89:343.</a></li><li><a class="nounderline abstract_t">Huang YT, Wang CC, Tsai CS, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2011; 80:429.</a></li><li><a class="nounderline abstract_t">Lea JS, Sheets EE, Duska LR, et al. Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection. Gynecol Oncol 2002; 84:285.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).</li><li><a class="nounderline abstract_t">Lea JS, Sheets EE, Wenham RM, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002; 84:115.</a></li><li><a class="nounderline abstract_t">Lissoni A, Gabriele A, Gorga G, et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 1997; 8:969.</a></li><li><a class="nounderline abstract_t">Zanetta G, Lissoni A, Gabriele A, et al. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Gynecol Oncol 1997; 64:431.</a></li><li><a class="nounderline abstract_t">Benedetti-Panici P, Greggi S, Scambia G, et al. Locally advanced cervical adenocarcinoma: is there a place for chemo-surgical treatment? Gynecol Oncol 1996; 61:44.</a></li><li><a class="nounderline abstract_t">Umesaki N, Izumi R, Fushiki H, et al. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol 1999; 75:142.</a></li><li><a class="nounderline abstract_t">Nagao S, Fujiwara K, Oda T, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 2005; 96:805.</a></li><li><a class="nounderline abstract_t">Rein DT, Kurbacher CM, Breidenbach M, et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 2002; 87:98.</a></li><li><a class="nounderline abstract_t">Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734.</a></li></ol></div><div id="topicVersionRevision">Topic 13929 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://seer.cancer.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : SEER data for 2003-2007: http://seer.cancer.gov/ (Accessed on September 21, 2017).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11002225" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557613" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926787" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507827" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207397" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303584" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910527" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739704" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686037" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cervical cancer and use of hormonal contraceptives: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473898" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prospective study of human papillomavirus and risk of cervical adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21211829" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15693030" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206285" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34629493" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2020 WHO Classification of Female Genital Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cervical cancer: what's new in classification, morphology, molecular findings and prognosis of glandular precursor and invasive lesions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cervical cancer: what's new in classification, morphology, molecular findings and prognosis of glandular precursor and invasive lesions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697450" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932559" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Stage IA1 cervical adenocarcinoma: definition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33784415" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33784415" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410344" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Analysis of prognostic features in adenocarcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2337867" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869095" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30720532" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051322" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16884367" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22293041" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451800" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517643" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063659" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145099" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266551" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic significance of adenocarcinoma histology in women with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827013" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519638" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11016467" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634986" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32435273" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of survival outcomes of locally advanced cervical cancer by histopathological types in the surveillance, epidemiology, and end results (SEER) database: a propensity score matching study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16300819" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ovarian metastasis in carcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427212" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764420" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284774" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966701" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21193227" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11972381" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308255" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Classification of radical hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28785898" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : 2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10472864" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early cervical adenocarcinoma: selection criteria for radical surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091590" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440805" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798694" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542643" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812088" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812088" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11748986" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402169" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062145" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626116" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Locally advanced cervical adenocarcinoma: is there a place for chemo-surgical treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502441" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721429" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468349" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552320" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Improved survival with bevacizumab in advanced cervical cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
